Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies
Journal article
Spencer AJ. et al, (2022), eBioMedicine, 77, 103902 - 103902
Detection and Quantification of Antibody to SARS CoV 2 Receptor Binding Domain provides enhanced Sensitivity, Specificity and Utility.
Journal article
Rosadas C. et al, (2022), Journal of virological methods
Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice
Journal article
Spencer AJ. et al, (2021), Nature Communications, 12
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Journal article
Flaxman A. et al, (2021), The Lancet, 398, 981 - 990
The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 Beta (B.1.351) and other variants of concern in preclinical studies
Journal article
Spencer AJ. et al, (2021)
Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice.
Journal article
Collins KA. et al, (2021), Scientific reports, 11
A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice
Journal article
Silva-Cayetano A. et al, (2021), Med, 2, 243 - 262.e8
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Journal article
Voysey M. et al, (2021), The Lancet, 397, 881 - 891
Publisher Correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
Journal article
van Doremalen N. et al, (2021), Nature, 590, E24 - E24
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Journal article
Barrett JR. et al, (2021), Nature Medicine, 27, 279 - 288
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Journal article
Ewer KJ. et al, (2021), Nature Medicine, 27, 270 - 278
Heterologous vaccination regimens with self-amplifying RNA and Adenoviral COVID vaccines induce robust immune responses in mice
Journal article
Spencer AJ. et al, (2021)
ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
Journal article
Lambe T. et al, (2021)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Journal article
Voysey M. et al, (2021), The Lancet, 397, 99 - 111
Solar inactivated Salmonella Typhimurium induces an immune response in BALB/c mice
Journal article
Ssemakalu CC. et al, (2021), Heliyon, 7, e05903 - e05903
Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19
Journal article
Graham SP. et al, (2020), npj Vaccines, 5
Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule
Journal article
Rollier CS. et al, (2020), Scientific Reports, 10
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Journal article
Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
Journal article
van Doremalen N. et al, (2020), Nature, 586, 578 - 582
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Journal article
Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478